Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T18:42:49.594Z.
Calculation as of: 2026-10-06T18:42:49.594Z.
Quote observation: 2026-10-06T18:40:09.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2e72a758e634708c28c06ae15f1e09243225437df43ff658102191b35b06d910
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$2.13B
EV/EBITDA Ratio
N/A
TTM Avg
156.56x
3Y Avg
157.08x
5Y Avg
157.08x
Market Cap
$2.13B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.11B
EV/EBITDA Ratio
12.86x
TTM Avg
13.80x
3Y Avg
16.03x
5Y Avg
17.55x
Market Cap
$2.21B
EV/EBITDA Ratio
15.32x
TTM Avg
9.40x
3Y Avg
61.74x
5Y Avg
31.90x
Market Cap
$2.07B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.07B
EV/EBITDA Ratio
65.86x
TTM Avg
96.19x
3Y Avg
628.91x
5Y Avg
603.99x
Market Cap
$2.07B
EV/EBITDA Ratio
N/A
TTM Avg
238.50x
3Y Avg
123.46x
5Y Avg
123.46x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pharvaris N.V. (PHVS) | $2.16B | N/A | N/A | N/A | N/A |
| GeneDx Holdings Corp. (WGS)vs › | $2.13B | N/A | 156.56x | 157.08x | 157.08x |
| SELLAS Life Sciences Group, Inc. (SLS)vs › | $2.13B | N/A | N/A | N/A | N/A |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 12.86x | 13.80x | 16.03x | 17.55x |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.21B | 15.32x | 9.40x | 61.74x | 31.90x |
| Vera Therapeutics, Inc. (VERA)vs › | $2.09B | N/A | N/A | N/A | N/A |
| Viridian Therapeutics, Inc. (VRDN)vs › | $2.07B | N/A | N/A | N/A | N/A |
| Vericel Corporation (VCEL)vs › | $2.07B | 65.86x | 96.19x | 628.91x | 603.99x |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.07B | N/A | 238.50x | 123.46x | 123.46x |
| Alvotech (ALVO)vs › | $2.07B | 41.83x | 33.53x | 180.18x | 180.18x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
